Radical prostatectomy versus watchful waiting for prostate cancer (Q24236564)

2

0 references

Ella Walsh

3

0 references

Harry Comber

4

0 references

Tony Fitzgerald

5

0 references

Meredith Wallace Kazer

Cochrane Database of Systematic Reviews

6

0 references

publication date

10 November 2010

0 references

published in

0 references

cites work

Experiences of randomization: interviews with patients and clinicians in the SPCG-IV trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Prostate-specific antigen levels as a predictor of lethal prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Prognostic markers under watchful waiting and radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Quality of life after radical prostatectomy or watchful waiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

European Study of Radical Prostatectomy: time trends in Europe, 1993-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Treatment of prostate cancer: watchful waiting, radical prostatectomy, and cryoablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

A multi-institutional evaluation of active surveillance for low risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Early prostate cancer 2005. New 2005 data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Urinary incontinence following treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Role of surgeon volume in radical prostatectomy outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Watchful waiting as a treatment option for localized prostate cancer in the PSA era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Early prostate cancer: is there a need for new treatment options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Active surveillance for prostate cancer: for whom?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Active surveillance versus radical treatment for favorable-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Biopsychosocial aspects of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Mental health in men treated for early stage prostate carcinoma: a posttreatment, longitudinal quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Natural history of localized prostate cancer. Preliminary data on progression and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Population-based study of long-term survival in patients with clinically localised prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Clinical events in prostate cancer lifestyle trial: results from two years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

A qualitative analysis of interviews of men with early stage prostate cancer: the Prostate Cancer Lifestyle Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

An update on randomized clinical trials in localized and locoregional prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

The treatment of prostate cancer: an overview of current options

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Localised carcinoma of the prostate: a paradigm of uncertainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Effect of treatment on quality of life among men with clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

A review of quality-of-life evaluations in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Radical prostatectomy or deferred treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be diffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Watchful waiting and active surveillance: the current position

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

20-year outcomes following conservative management of clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Incontinence and erectile dysfunction following radical prostatectomy: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Vaginal changes and sexuality in women with a history of cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Screening for prostate cancer with prostate-specific antigen: beware the biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Results of conservative management of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Early outcomes of active surveillance for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Waning sexual function--the most important disease-specific distress for patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Predicting quality of life after radical prostatectomy: results from CaPSURE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Early prostate cancer: clinical decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Natural History of Early, Localized Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Active surveillance for prostate cancer: trials and tribulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Surgical management of localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

The effect of erectile dysfunction on the quality of life of men after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Radical prostatectomy: making it a better operation in the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

What is low-risk prostate cancer and what is its natural history?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Watchful waiting in prostate cancer: review and policy proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Development of a complex intervention improved randomization and informed consent in a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic Value of Tumour Ploidy and Comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Factors Associated With Initial Therapy for Clinically Localized Prostate Cancer: Prostate Cancer Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

Short- and long-term mortality with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Survival associated with treatment vs observation of localized prostate cancer in elderly men

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Prospective, conservative management of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Prostate cancer treatment and quality of life

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Prospective validation of active surveillance in prostate cancer: the PRIAS study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

EAU guidelines on prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Changes in continence and health-related quality of life after curative treatment and watchful waiting of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Carcinoma of the prostate: a 15-year followup

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Radical prostatectomy may improve disease-specific mortality, but not overall survival compared with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

The management of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

A preliminary report on a patient-preference study to compare treatment options in early prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Active surveillance: an individualized approach to early prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Relationship of dietary protein and soy isoflavones to serum IGF-1 and IGF binding proteins in the Prostate Cancer Lifestyle Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

The development of erectile dysfunction in men treated for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

ACTIVE SURVEILLANCE WITH SELECTIVE DELAYED INTERVENTION: USING NATURAL HISTORY TO GUIDE TREATMENT IN GOOD RISK PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

How older patients' treatment preferences are influenced by disclosures about therapeutic uncertainty: surgery versus expectant management for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Management of patients with localized prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

Perceived stress and quality of life among prostate cancer survivors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006590.PUB2

7 January 2021

10.1002/14651858.CD006590.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

21069689

1 reference

Consolidated OpenCitations Corpus – April 2017